In this year's Advances in Asthma review, we discuss viral infections in asthmatic patients and potential therapeutic agents, the microbiome, novel genetic associations with asthma, air quality and climate effects on asthma, exposures during development and long-term sequelae of childhood asthma, patient-centered outcomes research, and precision medicine. In addition, we discuss application of biomarkers to precision medicine and new information on asthma medications. New evidence indicates that rhinovirus-triggered asthma exacerbations become more severe as the degree of sensitization to dust mite and mouse increase. The 2 biggest drivers of asthma severity are an allergy pathway starting with allergic sensitization and an environmental tobacco smoke pathway. In addition, allergic sensitization and blood eosinophils can be used to select medications for management of early asthma in young children. These current findings, among others covered in this review, represent significant steps toward addressing rapidly advancing areas of knowledge that have implications for asthma management.

在今年的《哮喘进展》评论中，我们讨论了哮喘患者的病毒感染和潜在的治疗剂，微生物组，与哮喘的新型遗传关联，空气质量和气候对哮喘的影响，儿童哮喘的发展过程和长期后遗症，患者以结果为中心的研究和精密医学。此外，我们讨论了生物标志物在精准医学中的应用以及有关哮喘药物的新信息。新的证据表明，随着对尘螨和小鼠的敏感性增加，鼻病毒引发的哮喘恶化更加严重。哮喘严重程度的两个最大驱动因素是从过敏性致敏开始的过敏途径和环境烟草烟雾途径。此外，变态反应致敏和血液嗜酸性粒细胞可用于选择治疗幼儿早期哮喘的药物。这些当前的发现以及本综述中涵盖的其他发现，代表着朝着迅速发展的，对哮喘管理有影响的知识领域迈出的重要一步。